251 related articles for article (PubMed ID: 29661415)
21. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
Miyares MA; Kuyumjian Y; Eaves S; Dollard E
J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
[TBL] [Abstract][Full Text] [Related]
22. Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.
Grottke O; van Ryn J; Zentai C; Gan G; Honickel M; Rossaint R; Ten Cate H; Spronk HMH
PLoS One; 2019; 14(1):e0209350. PubMed ID: 30615630
[TBL] [Abstract][Full Text] [Related]
23. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
[TBL] [Abstract][Full Text] [Related]
24. Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab: A Case Report.
Hofer S; Philipsenburg C; Weigand MA; Brenner T
A A Case Rep; 2016 Dec; 7(11):227-231. PubMed ID: 27669031
[TBL] [Abstract][Full Text] [Related]
25. Incomplete dabigatran reversal with idarucizumab.
Steele AP; Lee JA; Dager WE
Clin Toxicol (Phila); 2018 Mar; 56(3):216-218. PubMed ID: 28704111
[TBL] [Abstract][Full Text] [Related]
26. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
27. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
Tsai LK; Lin HJ; Chua SK; Liao PC; Yang YP; Chou PC; Lee CW; Lin MJ; Chen HM; Yeh JT; Li YH
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
[TBL] [Abstract][Full Text] [Related]
28. Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran.
Na SY; Mracsko E; van Ryn J; Veltkamp R
Ann Neurol; 2015 Jul; 78(1):137-41. PubMed ID: 25899749
[TBL] [Abstract][Full Text] [Related]
29. Idarucizumab for dabigatran overdose in a child.
Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
[No Abstract] [Full Text] [Related]
30. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
Pollack CV; Reilly PA; van Ryn J; Eikelboom JW; Glund S; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Royle G; Sellke FW; Stangier J; Steiner T; Verhamme P; Wang B; Young L; Weitz JI
N Engl J Med; 2017 Aug; 377(5):431-441. PubMed ID: 28693366
[TBL] [Abstract][Full Text] [Related]
31. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Rosenberg L; Gerstrøm G; Nybo M
Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Norris S; Ramael S; Ikushima I; Haazen W; Harada A; Moschetti V; Imazu S; Reilly PA; Lang B; Stangier J; Glund S
Br J Clin Pharmacol; 2017 Aug; 83(8):1815-1825. PubMed ID: 28230262
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
[TBL] [Abstract][Full Text] [Related]
34. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.
Brennan Y; Favaloro EJ; Pasalic L; Keenan H; Curnow J
Intern Med J; 2019 Jan; 49(1):59-65. PubMed ID: 29869387
[TBL] [Abstract][Full Text] [Related]
35. Idarucizumab for dabigatran overdose.
Peetermans M; Pollack C; Reilly P; Liesenborghs L; Jacquemin M; Levy JH; Weitz JI; Verhamme P
Clin Toxicol (Phila); 2016 Sep; 54(8):644-6. PubMed ID: 27224445
[TBL] [Abstract][Full Text] [Related]
36. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
[TBL] [Abstract][Full Text] [Related]
37. Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?
Miller L; Ferreira JA; Tucker C
J Emerg Med; 2017 Mar; 52(3):341-347. PubMed ID: 27727040
[TBL] [Abstract][Full Text] [Related]
38. Assessment of patients post reversal with idarucizumab.
Raco V; Ahuja T; Green D
J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
[TBL] [Abstract][Full Text] [Related]
39. The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation.
Božič Mijovski M; Malmström RE; Vene N; Antovic JP; Mavri A
Sci Rep; 2021 Mar; 11(1):5920. PubMed ID: 33723299
[TBL] [Abstract][Full Text] [Related]
40. Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal.
Stone L; Merriman E; Hanna M; Royle G; Chan H
Thromb Haemost; 2022 Jul; 122(7):1096-1103. PubMed ID: 34814227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
